FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds or to their pharmaceutically acceptable salts selected from: 1) 1-((3S,4R)-3-(5-chloro-2-(1-ethyl-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 2) 1-((3S,4R)-3-(5-chloro-2-(1-(2, 2-difluoroethyl)-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 3) 1-((3S,4R)-3-(5-chloro-2-(1-cyclopropyl-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 4) 1-((3S,4R)-3-(5-chloro-2-(isoxazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 5) 1-((3S,4R)-3-(5-chloro-2-(isothiazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 6) 4-((3S,4R)-1-acryloyl-4-fluoropiperidin-3-ylamino)-2-(1-ethyl-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 7) 4-((3S,4R)-1-acryloyl-4-fluoropiperidin-3-ylamino)-2-(1-(2,2-difluoroethyl)-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 8) 4-((3S,4R)-1-acryloyl-4-fluoropiperidin-3-ylamino)-2-(1-cyclopropyl-1H-pyrazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 9) 4-((3S,4R)-1-acryloyl-4-fluoropiperidin-3-ylamino)-2-(isoxazole-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 10) 1-((3S,4R)-3-(2-(1-ethyl-1H-pyrazol-4-ylamino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one, 11) 1-((3S,4R)-4-fluoro-3-(2-(isoxazol-4-ylamino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)prop-2-ene-1-one, and 12) 1-((3S,4S)-3-(5-chloro-2-(1-ethyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-4-fluoropiperidin-1-yl)prop-2-ene-1-one. The invention also relates to a pharmaceutical composition for inhibiting the activity of JAK3 and/or BTK, containing the above compounds or pharmaceutically acceptable salts thereof.
EFFECT: production of new compounds and a pharmaceutical composition based thereon, potentially applicable in medicine for treating inflammatory and proliferative diseases.
2 cl, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF OXIFLUOROPIPERIDINE AS A KINASE INHIBITOR | 2018 |
|
RU2758370C1 |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| AMINOMETHYLPIPERIDINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2756505C1 |
| PYRROLOTRIAZINE DERIVATIVES AS KINASE INHIBITOR | 2018 |
|
RU2726632C1 |
| METHODS FOR TREATMENT OF MALIGNANT TUMOR USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | 2016 |
|
RU2765154C2 |
| 6-[4-(1H-IMIDAZOL-2-YL)PIPERIDIN-1-YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | 2014 |
|
RU2674261C2 |
| METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS, USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK-INHIBITING ACTIVITY | 2016 |
|
RU2779287C2 |
| COMPOUNDS AND COMPOSITIONS FOR MODULATING KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2822389C2 |
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
